"From Proof of Concept to Revenue"... DEEPNOID's Generative Medical AI Expands Supply to Regional Hospitals

[Financial News] DEEPNOID's generative medical artificial intelligence (AI) business is moving beyond the proof-of-concept stage and expanding into actual supply to medical institutions.
After recently securing a reference at Pusan National University Hospital, the company has now added Chonnam National University Hwasun Hospital. Attention is turning to whether the rollout will accelerate, led by tertiary hospitals and regional hub medical institutions.
According to DEEPNOID on the 31st, the company signed a supply contract with Chonnam National University Hwasun Hospital for 'M4CXR,' a generative AI-based solution that creates preliminary chest X-ray reports.
Chonnam National University Hwasun Hospital is a tertiary hospital with more than 700 beds and a regional medical center responsible for treating severe patients in the Honam area. The contract is part of the Ministry of Health and Welfare (MOHW)'s project supporting AI-based care systems at regional responsible medical institutions.
What stands out is that the company has secured back-to-back real-world use references at tertiary hospitals, rather than a single supply deal. In medical AI, clinical usability and hospital references are considered key competitive advantages for follow-up adoption. The latest supply, following Pusan National University Hospital, is seen as a potential bridgehead for further expansion to other hospitals.
M4CXR uses generative AI to support the drafting of preliminary chest X-ray reports. DEEPNOID plans to expand its application to CT and MRI in the future, broadening the business into an AI service that supports medical staff across their workflow, beyond individual image interpretation.
The company has also recently completed regulatory approval from the Ministry of Food and Drug Safety for its software medical device, AxonFlow. By expanding its product lineup with generative AI and agentic AI as two pillars, the company is shifting its focus from technology development to clinical application and commercialization.
Choi Woo-sik, CEO of DEEPNOID, said, "As supply contracts for M4CXR continue to be signed one after another, we are confirming the potential for generative medical AI to spread in clinical settings." He added, "We will expand its application to various fields, including CT and MRI, going forward."
An industry official in the medical AI sector noted, "For medical AI, clinical references secured at actual tertiary hospitals are just as important as technological capability when deciding on follow-up adoption." The official added, "As more supply cases accumulate at regional hub hospitals, the likelihood of expansion to other medical institutions could also grow." 


[email protected] Kim Kyung-a Reporter